Oct 15, 2020|2 min readBy DDNews StaffLilly snaps up Disarm TherapeuticsLilly announces an agreement to acquire Disarm Therapeutics
Jul 12, 2019|3 min readBy DDNews StaffLilly’s migraine survey identifies treatment weak pointsLilly’s OVERCOME observational study reveals inconsistent and sub-optimal treatment landscape for migraine
May 22, 2019|2 min readBy DDNews StaffLilly’s lower-priced generic insulin hits the marketList price of Lilly’s Insulin Lispro Injection has 50 percent lower list price than branded Humalog
Apr 22, 2019|3 min readBy Mel J. YeatesLilly makes moves in ChinaLilly sells antibiotics and manufacturing facility to Eddingpharm, which will distribute the antibiotics in China
Infectious Disease & VaccinesOct 05, 2023|7 min readBy Stephanie DeMarco, PhDLighting up tuberculosis with point-of-care diagnosticsMireille Kamariza develops new chemistry-driven diagnostics for tuberculosis that can reduce the time to treatment from weeks to minutes.
Feb 08, 2012|2 min readBy Lloyd DunlapArecor adds LillyEli Lilly & Co. becomes latest partner to work with U.K. company on advanced formulations of protein therapeutics
May 09, 2018|2 min readBy DDNews StaffLilly acquires ARMO BioSciencesEli Lilly to acquire ARMO BioSciences for $1.6 billion in all-cash transaction
May 27, 2019|2 min readBy Mel J. YeatesLilly lands non-opioid pain assetLilly notes a licensing agreement for Centrexion Therapeutics’ non-opioid pain asset
Nov 09, 2015|2 min readBy Kelsey KaustinenIgnyta, Lilly ink license agreementIgnyta will pay Lilly $2 million and issue shares in return for an exclusive license to Lilly's taladegib program